Hinge Health (NYSE:HNGE - Free Report) had its target price increased by KeyCorp from $45.00 to $60.00 in a report published on Monday morning,Benzinga reports. KeyCorp currently has an overweight rating on the stock.
Other analysts have also issued research reports about the company. Evercore ISI started coverage on Hinge Health in a report on Monday, June 16th. They set an "outperform" rating and a $50.00 target price for the company. Royal Bank Of Canada initiated coverage on Hinge Health in a research note on Monday, June 16th. They set an "outperform" rating and a $45.00 price objective for the company. Needham & Company LLC started coverage on Hinge Health in a research note on Monday, June 16th. They issued a "buy" rating and a $47.00 target price on the stock. Barclays increased their price target on shares of Hinge Health from $43.00 to $51.00 and gave the company an "overweight" rating in a research report on Monday. Finally, Piper Sandler started coverage on shares of Hinge Health in a research report on Monday, June 16th. They issued an "overweight" rating and a $41.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat.com, Hinge Health currently has an average rating of "Moderate Buy" and a consensus price target of $49.36.
Read Our Latest Report on Hinge Health
Hinge Health Stock Performance
Shares of NYSE:HNGE traded up $0.55 during trading hours on Monday, hitting $48.19. The company's stock had a trading volume of 830,694 shares, compared to its average volume of 1,045,669. Hinge Health has a 52 week low of $33.42 and a 52 week high of $52.16.
About Hinge Health
(
Get Free Report)
Our vision is to build a new health system that transforms outcomes, experience and costs by using technology to scale and automate the delivery of care. Hinge Health leverages software, including AI, to largely automate care for joint and muscle health, delivering an outstanding member experience, improved member outcomes, and cost reductions for our clients.
See Also
Before you consider Hinge Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hinge Health wasn't on the list.
While Hinge Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
